CHICAGO — A genetic testing company largely lost its bid for dismissal of a putative class action accusing it of falsely marketing its genetic testing to screen in vitro-fertilized embryos for chromosomal abnormalities as being 98% accurate. The test purchasers sufficiently allege that Reproductive Genetic Innovations Inc. was aware of scientific research regarding problems with preimplantation genetic screening and should have known that its representations were misleading, a federal judge in Illinois ruled.
Read the ruling here .
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.
Search Articles
